Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer

Completed · Phase 3

Conditions studied: Prostate Cancer

In brief

Randomized phase III trial to compare the effectiveness of low, intermediate, and high dose suramin in treating men with stage IV prostate cancer that is refractory to hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of suramin is more effective for prostate cancer.

Key facts

Study ID
NCT00002723
Run by
National Cancer Institute (NCI)
People needed
390
Starts
1996-01-01
Expected to finish
2008-03-01
Last updated by the study team
2013-02-28

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.